曲妥珠单抗
医学
后天抵抗
肿瘤科
内科学
乳腺癌
药理学
癌症
作者
Keng Hsueh Lan,Chien‐Hsing Lu,Dihua Yu
标识
DOI:10.1196/annals.1339.026
摘要
A bstract : Trastuzumab (Herceptin™) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2‐positive breast tumors respond to trastuzumab as a single agent, and 2‐5% of trastuzumab‐treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI